Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Utility of restage transurethral resection of bladder tumor

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction:

          Transurethral resection of bladder tumor (TURBT) aims at complete resection of all the visible tumors. Existing guidelines recommend restage TURBT in all patients with T1 and high-grade tumors, to avoid under-staging. However, restage TURBT may not be plausible/feasible at all the times. This study was performed with an aim to better define the utility of restage TURBT in a tertiary care hospital of India.

          Methods:

          Patients with high grade/T1 tumors at the first TURBT were prospectively enrolled. Their demographic profile, previous cystoscopic findings, and histological reports were recorded. The primary objective was to assess the tumor detection and stage up-migration rates at restage TURBT. The secondary objectives was to identify factors predicting presence of tumor at restage TURBT. Patients were followed up to detect recurrence and progression for a minimum of 3 months.

          Results:

          Of 128 prospective patients’ enrolled, 29 patients were lost to follow-up and 11 patients did not undergo restage. A total of eighty-eight patients underwent restage TURBT of which twenty-eight patients (31.8%) had tumor at their second TURBT with five of these patients being upstaged to T2. The risk of having a tumor at restage was significantly higher in patients with solid tumors (56.2% vs. 26.4%, P = 0.02, 95% confidence interval: 0.035–0.024) but was independent of the tumor size ( P = 0.472), number of growths ( P = 0.267), grade of tumor ( P = 0.441), presence or absence of muscle at the initial TURBT ( P = 0.371) and place of initial TURBT ( P = 0.289). There was a significant difference in the recurrence and progression rates in patients who had tumor at restage as compared to those who did not (recurrence; 33.3% and 23.8%, P = 0.022, respectively vs. progression; 11.1% and 3.7% respectively, P = 0.07; mean follow-up = 10.8 months).

          Conclusions:

          We conclude that restage TURBT is necessary in patients with solid looking tumors and the presence of tumor at restage confers a higher risk of recurrence and progression.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found

          The value of a second transurethral resection in evaluating patients with bladder tumors.

          H W Herr (1999)
          The role of a routine second transurethral resection in evaluating and managing bladder tumors is defined. From January to October 1998, 150 patients with new or recurrent bladder tumors underwent repeat transurethral resection within 2 to 6 weeks after the initial resection, and the results, including the presence of residual tumor and tumor stage, were compared. Of the 150 cases 36 (24%) had no and 114 (76%) had residual tumor on repeat transurethral resection. Of 96 cases with superficial (Ta, Tis, T1) bladder tumors 72 (75%) had residual noninvasive tumor and 28 (29%) were up staged to invasive tumor. Among 54 patients with a muscle invasive tumor 12 (22%) had no residual tumor on repeat transurethral resection. Results of the second resection changed tumor treatment in 50 patients (33%). Many patients with bladder tumors have tumor present after an initial trans-urethral resection. Routine repeat resection is advised to control noninvasive tumors and to detect residual tumor invasion.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Quality control in transurethral resection of bladder tumours.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.

              We compared the outcomes of repeat transurethral resection plus intravesical mitomycin C with initial transurethral resection of bladder plus intravesical MMC in patients with newly diagnosed pT1 transitional cell carcinoma of the bladder in terms of recurrence, progression and overall survival. Of 148 newly diagnosed patients with T1 bladder cancer 142 were prospectively randomized in 2 groups between January 2001 and January 2005. A total of 74 patients underwent second TURB and received adjuvant MMC intravesically (group 1) and 68 patients received adjuvant MMC following the initial TURB (group 2). All repeat TURB operations were performed 2 to 6 weeks following initial TURB. Patients with incomplete resection, Cis or muscle invasive disease were excluded from study. The first dose of mitomycin C (40 mg per week for a total of 8 weeks) was instilled intravesically in all patients during the first 24 hours after the last surgery. Mean followup was 31.5 months (range 6 to 48) with no difference between the 2 groups. The rate of recurrence-free survival was 86.35% (SE 0.4%), 77.67% and 68.72% in group 1, and 47.08%, 42.31% and 37.01% in group 2 for the first, second and third year, respectively (overall 74.32% vs 36.76%, log rank 0.0001). Recurrence was observed in 19 of the 74 (25.68%) patients in group 1 and in 43 of the 68 (63.24%) patients in group 2. Ten of the 19 (52.63%) patients in group 1 and 35 of the 43 (81.39%) patients in group 2 had recurrence within 12 months. Recurrence was observed in 17.6%, 25% and 60% of patients with G1, G2 and G3 tumors, respectively, in group 1. The same rates for group 2 were 25%, 64% and 90%. The RFS rate was significantly worse in the high grade group (G2 and G3) (p <0.001). Progression was observed at 4.05% for group 1 compared to 11.76% for group 2 (log rank 0.0974). OS was 91.89% and 89.71% in group 1 and 2, respectively (log rank 0.732). The high recurrence rate in patients who did not undergo ReTUR is due to a high residual tumor rate following initial TURB. The benefit of ReTUR is especially true for high grade tumors. Since intravesical MMC was present in both groups, this study has shown that intravesical chemotherapy does not compensate for inadequate resection. Progression does not seem to be affected by ReTUR although there was a trend favoring the ReTUR group. We recommend ReTUR for patients with primary high grade T1 disease to achieve better recurrence-free survival.
                Bookmark

                Author and article information

                Journal
                Indian J Urol
                Indian J Urol
                IJU
                Indian Journal of Urology : IJU : Journal of the Urological Society of India
                Medknow Publications & Media Pvt Ltd (India )
                0970-1591
                1998-3824
                Oct-Dec 2018
                : 34
                : 4
                : 273-277
                Affiliations
                [1]Department of Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
                [1 ]Department of Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
                Author notes
                Article
                IJU-34-273
                10.4103/iju.IJU_218_17
                6174718
                a270c72f-0fa5-4587-a575-0ab2738b4752
                Copyright: © 2018 Indian Journal of Urology

                This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

                History
                : 23 August 2017
                : 04 July 2018
                Categories
                Original Article

                Urology
                Urology

                Comments

                Comment on this article